{"gene":"LPA","run_date":"2026-06-10T02:59:50","timeline":{"discoveries":[{"year":1983,"finding":"Lp(a) lipoprotein contains two polypeptide chains: apolipoprotein B-100 (identical to LDL apoB) and a high-molecular-weight glycoprotein (~350 kDa) carrying the specific Lp(a) immunoreactivity. These two components are linked by disulfide bonds in the native lipoprotein, as the unreduced delipidized protein moiety runs as a single ~700 kDa band on SDS-PAGE.","method":"SDS-polyacrylamide gel electrophoresis under reducing and non-reducing conditions, immunochemical analysis, periodate-Schiff staining","journal":"FEBS letters","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct biochemical reconstitution/characterization with multiple orthogonal methods (gel electrophoresis, immunoprecipitation, reducing vs non-reducing conditions), foundational structural result independently confirmed by later work","pmids":["6219896"],"is_preprint":false},{"year":1987,"finding":"Lp(a) glycoprotein (apo(a)) exhibits inter- and intraindividual size heterogeneity (apparent MW ~400,000–700,000 Da), and phenotypic differences between apo(a) isoforms do not reside in the sialic acid moiety (neuraminidase treatment does not abolish size differences). Family studies indicate phenotypes are controlled by a series of autosomal alleles at a single locus, and isoform size is inversely associated with plasma Lp(a) concentration.","method":"SDS-gel electrophoresis under reducing conditions, immunoblotting with anti-Lp(a) serum, neuraminidase treatment, family studies","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — direct biochemical characterization combined with enzymatic treatment and family genetic analysis; foundational finding replicated across subsequent studies","pmids":["2956279"],"is_preprint":false},{"year":1981,"finding":"Lp(a) lipoprotein enters cultured fibroblasts independently of the LDL receptor: processing of 125I-Lp(a) was not saturated at high concentrations, was largely receptor-independent (only slightly higher in normal vs. receptor-negative cells), and Lp(a) did not compete with 125I-LDL for receptor-mediated fibroblast association, although it inhibited LDL degradation in a time-dependent manner.","method":"125I-labeled ligand binding and degradation assays in fibroblasts from normal, FH heterozygous, and LDL receptor-negative FH homozygous subjects","journal":"Clinical genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct receptor-ligand assay with genetically defined receptor-deficient cells; clean negative result for LDL receptor involvement, replicated concept in multiple later studies","pmids":["6277537"],"is_preprint":false},{"year":1997,"finding":"The VLDL receptor mediates endocytosis and lysosomal degradation of Lp(a). Fibroblasts expressing human VLDL receptor catabolize Lp(a); receptor-deficient fibroblasts do not. Antibodies against VLDL receptor and RAP (a receptor antagonist) block Lp(a) degradation. Catabolism is inhibited by apolipoprotein(a) but not by LDL or anti-apoB antibodies, indicating that apo(a) mediates Lp(a) binding to the VLDL receptor. In vivo, Lp(a) clearance is delayed in VLDL receptor-deficient mice.","method":"Receptor-expressing vs. receptor-deficient fibroblast assays, antibody and RAP inhibition, in vivo mouse clearance studies, immunohistochemistry of human atherosclerotic lesions","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (cell-based catabolism, antibody inhibition, RAP competition, in vivo mouse model), consistent results across assays","pmids":["9410893"],"is_preprint":false},{"year":1995,"finding":"Lp(a) interacts directly with plasminogen binding sites on monocytoid U937 cells and endothelial cells in a time-dependent, specific, saturable, divalent ion-independent, and temperature-sensitive manner with affinity similar to plasminogen (Kd ~1–3 μM), but binds to ~10-fold fewer sites. Gangliosides and cell-surface proteins with C-terminal lysyl residues (including enolase) inhibit Lp(a) binding, indicating shared plasminogen receptor sites.","method":"Binding assays with radiolabeled Lp(a) on U937 and endothelial cells; competitive inhibition with gangliosides, enolase, and lysine analogs; saturation binding kinetics","journal":"Thrombosis and haemostasis","confidence":"High","confidence_rationale":"Tier 2 / Strong — quantitative binding assays with Kd determination, multiple competitive inhibitors tested, two cell types used","pmids":["7667829"],"is_preprint":false},{"year":1999,"finding":"A G→A substitution at the +1 donor splice site of the apo(a) kringle IV type 8 intron occurs in ~6% of Caucasians and causes congenital Lp(a) deficiency. This mutation leads to alternative splicing producing a truncated apo(a). The truncated apo(a) is secreted but cannot form the covalent Lp(a) complex (disulfide-linked apo(a)/apoB-100 complex), resulting in rapid degradation of free apo(a) in plasma.","method":"RT-PCR of apo(a) illegitimate transcription, expression of alternatively spliced cDNA in HepG2 cells, immunoprecipitation of plasma apo(a)","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — splice site mutation characterized by RT-PCR, functional consequence established by cell expression system, plasma protein analysis in homozygotes; multiple orthogonal methods in one study","pmids":["10484779"],"is_preprint":false},{"year":2006,"finding":"Cultured human hepatoma cells secrete an extracellular oxidase activity that dramatically enhances the rate of covalent (disulfide bond) Lp(a) assembly. This activity is heat-sensitive and protein-based (retained after ultrafiltration >5 kDa), requires a small-molecule cofactor (lost upon dialysis), and exhibits a ping-pong reaction mechanism kinetically analogous to protein disulfide isomerase. Protein disulfide isomerase itself was ruled out as the responsible enzyme.","method":"In vitro Lp(a) assembly assay with hepatoma cell-conditioned medium, heat inactivation, ultrafiltration, dialysis, kinetic analysis (Km, Vmax, rectangular hyperbola fitting)","journal":"Biochemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro biochemical assay with multiple mechanistic controls and kinetic characterization; single lab, identity of the oxidase not established","pmids":["16893192"],"is_preprint":false},{"year":1997,"finding":"Lp(a) assembly occurs via a two-step mechanism: (1) noncovalent interactions between apo(a) kringle domains (particularly T-6 and T-7) and circulating LDL, followed by (2) formation of a single disulfide bridge to stabilize the Lp(a) complex. Circulating Lp(a) interacts with kidney cells, where a collagenase-type protease cleaves the N-terminal ~2/3–3/4 of apo(a), with apo(a) fragments found in urine. The core Lp(a) particle is subsequently cleared by the liver.","method":"Biochemical analysis of Lp(a) assembly intermediates, identification of apo(a) fragments in urine, in vitro binding studies with kringle domain variants","journal":"Clinical genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mechanistic model supported by biochemical data from same lab; some elements inferred rather than directly demonstrated in single paper","pmids":["9520125"],"is_preprint":false},{"year":2022,"finding":"Apo(a) and apoB interact noncovalently within hepatocytes before Lp(a) is secreted. Noncovalent apo(a)/apoB complexes (but not covalent ones) are present in cell lysates. Apo(a) and apoB colocalize in the ER, trans-Golgi, and early endosomes. The noncovalent interaction (mediated by lysine-binding sites 7 and 8 of apo(a)) is required for coupling of apo(a) and Lp(a)-apoB secretion: PCSK9 treatment enhances and lomitapide reduces apo(a) secretion in a manner dependent on this interaction; siRNA knockdown of APOB reduces apo(a) secretion.","method":"Co-immunoprecipitation, co-immunofluorescence, proximity ligation assay, pulse-chase metabolic labeling, siRNA knockdown, pharmacological manipulation (PCSK9, lomitapide) in human hepatocellular carcinoma cells expressing wild-type and LBS-mutant 17K apo(a)","journal":"Arteriosclerosis, thrombosis, and vascular biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (Co-IP, co-IF, PLA, pulse-chase), genetic and pharmacological perturbations, clear mechanistic readouts in a single rigorous study","pmids":["35045727"],"is_preprint":false},{"year":1993,"finding":"Lp(a) binding to hepatoma cells (HepG2) is predominantly of low affinity and non-saturable (unlike LDL which shows saturable high-affinity binding). Preincubation with Lp(a) or free apo(a) for 48–72 h paradoxically increases subsequent 125I-LDL binding (>2-fold) through a mechanism not involving the LDL receptor (not blocked by anti-LDL receptor antibodies). Coincubation with LDL significantly increases Lp(a) degradation by HepG2 cells, suggesting 'hitchhiking' uptake.","method":"Radioligand binding assays with 125I-LDL and 125I-Lp(a) in HepG2 and Hep3B cells, antibody inhibition, preincubation experiments","journal":"Arteriosclerosis and thrombosis","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — quantitative binding assays with receptor blocking, two hepatoma cell lines tested; single lab","pmids":["8318510"],"is_preprint":false},{"year":1999,"finding":"Chondroitin sulfate proteoglycans in smooth muscle cell extracellular matrix bind both Lp(a) and LDL with high affinity. Lp(a) pre-bound to matrix increases subsequent LDL binding 2–3-fold, with the additional LDL held predominantly by strong non-ionic associations (vs. ~50% ionic for LDL-pretreated matrix), providing a mechanism for cooperative lipoprotein accumulation in arterial lesions.","method":"Radioligand binding assays with cultured human arterial smooth muscle cell matrix, chondroitinase/proteoglycan analysis, binding affinity measurements","journal":"Arteriosclerosis, thrombosis, and vascular biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct binding assays with matrix components identified; enzymatic characterization of interaction type; single lab","pmids":["10323765"],"is_preprint":false},{"year":1990,"finding":"Lp(a) forms complexes with glycosaminoglycans (GAG) and proteoglycans (PG) from human aorta with a higher GAG/lipoprotein ratio than LDL. The Lp(a) lacking apo(a) (Lpa-) shows intermediate reactivity between Lp(a) and LDL, indicating apo(a) contributes to but is not solely responsible for the enhanced proteoglycan binding. Lp(a)-glycan complexes incubated with mouse peritoneal macrophages cause cholesteryl ester accumulation and foam cell formation, with the degree of accumulation correlating with proteoglycan reactivity.","method":"In vitro complex formation assays with isolated GAG/PG and lipoproteins, macrophage incubation with lipoglycan complexes, cholesterol ester measurement","journal":"European heart journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct biochemical binding assays with apo(a)-depleted particles as control, functional foam cell readout; single lab","pmids":["2146124"],"is_preprint":false},{"year":1998,"finding":"Lp(a) stimulates expression of VCAM-1 and E-selectin in cultured human coronary artery endothelial cells (HCAEC) via a rise in intracellular free calcium. This effect is blocked by the intracellular calcium chelator BAPTA/AM. Recombinant apo(a) competes with Lp(a) and attenuates adhesion molecule expression, indicating apo(a) mediates this effect. The LDL receptor, VLDL receptor (RAP-insensitive), LDL receptor-related protein, cell-surface proteoglycans, and plasminogen receptors are not involved in this Lp(a)-induced adhesion molecule production.","method":"Cell culture with human coronary artery endothelial cells, VCAM-1/E-selectin protein measurement, intracellular calcium chelation (BAPTA/AM), competitive inhibition with recombinant apo(a), antibody/enzyme blocking of candidate receptors","journal":"FASEB journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple receptor-blocking experiments, calcium-dependence established pharmacologically, recombinant apo(a) competition; single lab","pmids":["9837867"],"is_preprint":false},{"year":2015,"finding":"Recombinant apo(a) containing 17 kringle IV domains induces IL-8 mRNA and protein expression in THP-1 and U937 macrophages via oxidized phospholipids (oxPL) carried on apo(a). Mutation of the lysine-binding site in kringle IV type 10 abolishes oxPL on apo(a) and blunts IL-8 induction. Enzymatic removal of oxPL from apo(a) significantly reduces this effect. The effect is mediated through CD36 and TLR2 receptors, downstream MAPK signaling (JNK and ERK1/2), and requires both NF-κB and AP-1 binding sites in the IL-8 promoter.","method":"siRNA receptor knockdown, MAPK inhibitors, luciferase reporter gene assays with IL-8 promoter mutants, enzymatic oxPL removal, trypsin digestion, LBS-mutant apo(a) in macrophage cell lines","journal":"Journal of lipid research","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (siRNA, pharmacological inhibition, promoter mutagenesis, enzymatic modification of ligand), two macrophage cell lines, clear mechanistic pathway defined in one study","pmids":["26474593"],"is_preprint":false},{"year":1996,"finding":"PAF-acetylhydrolase (PAF-AH) activity is associated with Lp(a) particles in human plasma. Removal of apo(a) from Lp(a) by reductive cleavage with DTT releases only ~15% of total PAF-AH activity, indicating that most PAF-AH is associated with the lipid/apoB core of Lp(a) rather than with apo(a) itself. Kinetic constants (Km, Vmax) differ significantly between small and large apo(a) isoforms. During Cu2+-induced Lp(a) oxidation, PAF-AH Vmax decreases significantly and extensive phosphatidylcholine hydrolysis to lyso-PC occurs.","method":"Density gradient ultracentrifugation, DTT reductive cleavage, PAF-AH activity assay, Cu2+-induced oxidation kinetics, lipid analysis by phospholipid assay","journal":"Atherosclerosis","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — enzymatic activity measured directly on isolated Lp(a) with apo(a) removal control; kinetic characterization across isoforms; single lab","pmids":["8831934"],"is_preprint":false},{"year":1991,"finding":"Lp(a) is oxidized by Cu2+ more slowly than LDL from the same donor (1.2–2.4-fold longer lag phase). The extended lag phase of Lp(a) is attributable to its higher sialic acid (NANA) content: neuraminidase treatment drastically shortens the Lp(a) lag phase, and re-supplementation with NANA at physiological concentrations restores it. LDL lag phase is not significantly affected by neuraminidase.","method":"Paired Cu2+-induced lipid peroxidation assays on isolated Lp(a) and LDL, neuraminidase treatment, NANA reconstitution, fatty acid and antioxidant composition analysis","journal":"Biochimica et biophysica acta","confidence":"Medium","confidence_rationale":"Tier 1–2 / Moderate — in vitro biochemical assay with enzymatic treatment and rescue experiment; paired samples from seven donors; single lab","pmids":["1825020"],"is_preprint":false},{"year":1995,"finding":"Lp(a) down-regulates glucocorticoid receptor (GR) gene expression and nuclear GR protein levels in human and rat vascular smooth muscle cells (SMC), but not in rat endothelial cells. GR mRNA decreases to 23% of control after 12 h Lp(a) treatment; nuclear GR protein falls to 55% after 48 h. LDL, VLDL, and HDL have no effect on GR in SMC. As a functional consequence, the antiproliferative effect of glucocorticoids on SMC is blunted by Lp(a) exposure.","method":"Radioligand binding assay for nuclear GR, Northern blotting for GR mRNA, cell proliferation assay, comparison across lipoprotein types and cell types","journal":"Endocrinology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mRNA and protein measured with functional proliferation readout; cell-type and lipoprotein-type specificity controls included; single lab","pmids":["7649076"],"is_preprint":false},{"year":1999,"finding":"Lp(a) behaves as a negative acute-phase reactant: plasma Lp(a) concentrations decline abruptly and transiently during sepsis and major burns, inversely mirroring CRP levels and paralleling LDL-C changes. This decline is not accompanied by increases in plasma apo(a) fragments or urinary apo(a), suggesting decreased production rather than increased degradation/shedding. Mouse turnover studies show that LPS treatment retards Lp(a) clearance, indicating that the reduction is not due to enhanced catabolism.","method":"Serial plasma measurements in ICU patients (sepsis, burns), apo(a) fragment immunoassay, urinary apo(a) measurement, mouse Lp(a) clearance study with LPS challenge","journal":"Arteriosclerosis, thrombosis, and vascular biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — human clinical serial measurements combined with mechanistic mouse clearance study; multiple measurement approaches; single lab","pmids":["10764684"],"is_preprint":false},{"year":2015,"finding":"Oxidized Lp(a) (oxLp(a)) induces autophagy in human umbilical vein endothelial cells (HUVECs) via a reactive oxygen species (ROS)-dependent mechanism. The PARP-1–LKB1–AMPK–mTOR and LKB1–AMPK–mTOR signaling pathways mediate this autophagic response. Superoxide dismutase (antioxidant) inhibits oxLp(a)-induced autophagy, confirming ROS dependence.","method":"Autophagy assays in HUVECs, ROS measurement, pathway inhibitor studies (PARP-1, LKB1, AMPK, mTOR), SOD treatment, Western blotting for pathway components","journal":"Atherosclerosis","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple pathway components probed with functional readout; single lab, single cell type","pmids":["26407666"],"is_preprint":false},{"year":2017,"finding":"Autotaxin (ATX), a lysophospholipase D, interacts with Lp(a) and promotes mineralization of the aortic valve, linking Lp(a) to calcific aortic valve disease (CAVD) pathobiology.","method":"Referenced as recent mechanistic data in review; original experimental work cited within the review paper","journal":"Expert review of cardiovascular therapy","confidence":"Low","confidence_rationale":"Tier 3 / Weak — mechanistic claim presented in a review without full experimental detail available in this abstract; original supporting experiment not directly described","pmids":["28816078"],"is_preprint":false},{"year":1999,"finding":"Lp(a) induces apoptosis in human umbilical vein endothelial cells (HUVECs) and rabbit aorta, with oxidized Lp(a) (oxLp(a)) being more potent than oxLDL. oxLp(a) stimulates superoxide (O2-) formation in HUVECs (356% increase) and rabbit aorta (294% increase). Apoptosis induction by oxLp(a) involves O2- as a mediator: it is enhanced by the SOD inhibitor DDTC and blunted by SOD and catalase. Lysophosphatidylcholine content is 7-fold higher in oxLp(a) vs. native Lp(a).","method":"DNA fragmentation assay, Annexin V assay, TUNEL staining, O2- measurement, SOD/catalase treatment, SOD inhibitor (DDTC), lysoPC quantification in HUVECs and rabbit aorta segments","journal":"Kidney international","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — two cell/tissue systems, pharmacological ROS manipulation with both enhancer and inhibitor controls, multiple apoptosis assays; single lab","pmids":["10201010"],"is_preprint":false},{"year":1998,"finding":"Elevated Lp(a) concentrations in patients with familial hypercholesterolemia (FH) are due to an effect of the LDL receptor deficiency on Lp(a) metabolism, independent of apo(a) genotype. Sib-pair analysis of siblings identical-by-descent at the apo(a) locus but differing in LDLR mutation status shows significantly higher Lp(a) in FH siblings, establishing a quantitative genetic interaction between LDLR status and Lp(a) levels.","method":"Sib-pair genetic analysis with IBD determination at apo(a) locus, LDLR mutation genotyping, Lp(a) plasma measurement in 367 family members of 60 index patients","journal":"European journal of human genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic epistasis by sib-pair design controlling for apo(a) genotype; large family-based study; single analysis","pmids":["9781014"],"is_preprint":false}],"current_model":"Lp(a) is a disulfide-linked complex of apolipoprotein B-100 and the plasminogen-homologous glycoprotein apo(a), assembled via a two-step process in which noncovalent apo(a)/apoB interactions occur intracellularly within hepatocytes (in the ER and Golgi) before an extracellular oxidase activity catalyzes covalent disulfide bond formation; plasma levels are determined primarily by the LPA locus (apo(a) isoform size inversely correlating with concentration), modulated by LDLR status; the particle is catabolized via the VLDL receptor (mediated by apo(a)) and not via the classical LDL receptor; apo(a)'s oxidized phospholipid (oxPL) cargo drives proinflammatory signaling in macrophages through CD36/TLR2–MAPK–NF-κB/AP-1 pathways, while Lp(a) also promotes endothelial dysfunction via calcium-dependent VCAM-1/E-selectin induction, binds plasminogen receptors on cell surfaces to compete with plasminogen activation, accumulates in arterial extracellular matrix through chondroitin sulfate proteoglycan interactions, and down-regulates glucocorticoid receptor expression in vascular smooth muscle cells."},"narrative":{"mechanistic_narrative":"LPA encodes apolipoprotein(a) (apo(a)), a plasminogen-homologous, kringle-rich glycoprotein that assembles with apolipoprotein B-100 to form the lipoprotein particle Lp(a), a determinant of atherothrombotic and vascular pathobiology [PMID:6219896, PMID:2956279]. The native particle is a disulfide-linked complex of apoB-100 and a ~350 kDa apo(a) glycoprotein that displays genetically determined size heterogeneity, with isoform size inversely correlating with plasma concentration and the phenotype controlled by a series of autosomal alleles at a single locus [PMID:6219896, PMID:2956279]. Assembly is a two-step process: apo(a) and apoB first associate noncovalently through apo(a) lysine-binding sites 7 and 8 inside hepatocytes, where the two proteins colocalize in the ER, trans-Golgi, and early endosomes, and this interaction is required for coupled secretion of both chains [PMID:9520125, PMID:35045727]; covalent disulfide bond formation is subsequently accelerated by a secreted, cofactor-dependent extracellular hepatoma oxidase activity kinetically analogous to but distinct from protein disulfide isomerase [PMID:16893192]. A splice-site mutation in the apo(a) kringle IV type 8 intron produces a truncated apo(a) that is secreted but cannot form the covalent complex and is rapidly degraded, causing congenital Lp(a) deficiency [PMID:10484779]. Lp(a) is catabolized via the VLDL receptor through apo(a)-mediated binding rather than the classical LDL receptor, while LDL receptor status nonetheless modulates plasma Lp(a) levels [PMID:6277537, PMID:9410893, PMID:9781014]. Functionally, apo(a) engages cell-surface plasminogen receptor sites carrying C-terminal lysines, competing with plasminogen [PMID:7667829]; its oxidized-phospholipid cargo drives proinflammatory IL-8 induction in macrophages through CD36/TLR2–MAPK–NF-κB/AP-1 signaling [PMID:26474593]; and Lp(a) promotes endothelial VCAM-1/E-selectin expression via a calcium-dependent, receptor-independent mechanism [PMID:9837867]. Lp(a) accumulates in arterial extracellular matrix through chondroitin sulfate proteoglycan and glycosaminoglycan interactions that promote foam cell formation [PMID:10323765, PMID:2146124], down-regulates glucocorticoid receptor expression in vascular smooth muscle cells [PMID:7649076], and in its oxidized form drives endothelial apoptosis and autophagy through ROS-dependent pathways [PMID:26407666, PMID:10201010].","teleology":[{"year":1983,"claim":"Establishing the molecular composition of Lp(a) was the first step: the question was what distinguishes Lp(a) from LDL, answered by showing it is apoB-100 disulfide-linked to a distinct high-molecular-weight glycoprotein.","evidence":"SDS-PAGE under reducing/non-reducing conditions with immunochemical and periodate-Schiff analysis","pmids":["6219896"],"confidence":"High","gaps":["Did not localize the disulfide bond or define the apo(a) sequence","Site and timing of disulfide formation unaddressed"]},{"year":1987,"claim":"Defined the genetic basis of plasma Lp(a) variation by showing apo(a) size heterogeneity is allelic at a single locus and inversely related to concentration, framing LPA as the primary determinant of Lp(a) levels.","evidence":"Reducing SDS-PAGE/immunoblotting, neuraminidase treatment, and family studies","pmids":["2956279"],"confidence":"High","gaps":["Did not establish the molecular mechanism linking isoform size to concentration","Sialic acid excluded but other structural contributors not defined"]},{"year":1981,"claim":"Tested whether Lp(a) uses the LDL receptor pathway and found it does not, opening the question of an alternative catabolic route.","evidence":"125I-ligand binding/degradation in normal, FH-heterozygous, and LDL-receptor-negative fibroblasts","pmids":["6277537"],"confidence":"High","gaps":["Did not identify the actual uptake receptor","Mechanism of Lp(a) inhibition of LDL degradation unresolved"]},{"year":1993,"claim":"Probed hepatic handling of Lp(a) and showed it binds hepatoma cells with low-affinity non-saturable kinetics and may be cleared by LDL-dependent 'hitchhiking', refining the catabolic model.","evidence":"Radioligand binding/degradation in HepG2 and Hep3B cells with antibody inhibition","pmids":["8318510"],"confidence":"Medium","gaps":["Single lab","Molecular identity of the hepatic binding site not defined"]},{"year":1995,"claim":"Connected apo(a) structural homology to function by demonstrating Lp(a) binds plasminogen receptor sites bearing C-terminal lysines, providing a mechanism for interference with fibrinolysis.","evidence":"Saturation binding of radiolabeled Lp(a) on U937 and endothelial cells with ganglioside/enolase/lysine-analog competition","pmids":["7667829"],"confidence":"High","gaps":["Did not quantify the functional impact on plasminogen activation in vivo","Specific receptor proteins not all identified"]},{"year":1997,"claim":"Identified the VLDL receptor as a genuine Lp(a) catabolic receptor, with apo(a) rather than apoB mediating binding, resolving the long-standing alternative-pathway question.","evidence":"Receptor-expressing vs deficient fibroblasts, antibody/RAP inhibition, VLDLR-deficient mouse clearance, lesion immunohistochemistry","pmids":["9410893"],"confidence":"High","gaps":["Relative in vivo contribution of VLDLR vs other routes unquantified","Does not explain hepatic clearance of the core particle"]},{"year":1997,"claim":"Proposed a two-step assembly model (noncovalent kringle-LDL interaction then disulfide stabilization) plus renal proteolytic processing, framing where and how Lp(a) is built and cleared.","evidence":"Biochemical analysis of assembly intermediates, urinary apo(a) fragment identification, kringle-variant binding studies","pmids":["9520125"],"confidence":"Medium","gaps":["Some steps inferred rather than directly demonstrated","Identity of the renal protease not established"]},{"year":2006,"claim":"Addressed how covalent assembly is catalyzed by identifying a secreted, cofactor-dependent hepatoma oxidase activity that accelerates disulfide bond formation, distinct from PDI.","evidence":"In vitro Lp(a) assembly assay with conditioned medium, heat/ultrafiltration/dialysis fractionation, ping-pong kinetic analysis","pmids":["16893192"],"confidence":"Medium","gaps":["Molecular identity of the oxidase not established","Single lab; cofactor not identified"]},{"year":2022,"claim":"Localized the noncovalent assembly step inside hepatocytes and showed it governs coupled apo(a)/apoB secretion, integrating assembly with cellular trafficking and secretion control.","evidence":"Co-IP, co-IF, PLA, pulse-chase, APOB siRNA, PCSK9/lomitapide perturbation in hepatocellular carcinoma cells with LBS-mutant apo(a)","pmids":["35045727"],"confidence":"High","gaps":["Did not identify the extracellular oxidase coupling to covalent assembly","Performed in a 17K isoform context"]},{"year":1999,"claim":"Defined a genetic cause of Lp(a) deficiency: a kringle IV-8 splice-donor mutation yielding truncated apo(a) that cannot form the covalent complex and is degraded, directly linking assembly competence to plasma persistence.","evidence":"RT-PCR of apo(a) transcription, expression of spliced cDNA in HepG2, plasma apo(a) immunoprecipitation","pmids":["10484779"],"confidence":"High","gaps":["Did not establish disease/phenotypic consequences of deficiency","Why free truncated apo(a) is rapidly cleared not fully resolved"]},{"year":1998,"claim":"Demonstrated genetic epistasis between LDLR status and Lp(a) levels independent of apo(a) genotype, showing LDLR deficiency raises Lp(a) despite LDLR not being the catabolic receptor.","evidence":"Sib-pair IBD analysis at the apo(a) locus with LDLR genotyping across 367 family members","pmids":["9781014"],"confidence":"Medium","gaps":["Mechanism reconciling LDLR effect on levels with non-LDLR catabolism unresolved","Single analysis"]},{"year":1990,"claim":"Linked Lp(a) to matrix retention and foam cell formation by showing enhanced proteoglycan/GAG complex formation driving macrophage cholesteryl ester accumulation, partly attributable to apo(a).","evidence":"In vitro GAG/PG complex formation, macrophage incubation, cholesteryl ester measurement with apo(a)-depleted controls","pmids":["2146124"],"confidence":"Medium","gaps":["Single lab","Apo(a)-independent component of binding not fully explained"]},{"year":1999,"claim":"Showed cooperative matrix accumulation: smooth muscle cell chondroitin sulfate proteoglycans bind Lp(a) and pre-bound Lp(a) enhances subsequent LDL retention, a mechanism for lesional lipoprotein deposition.","evidence":"Radioligand binding to SMC matrix, chondroitinase analysis, binding affinity measurements","pmids":["10323765"],"confidence":"Medium","gaps":["Non-ionic interaction partners not molecularly defined","Single lab"]},{"year":1998,"claim":"Identified an endothelial pro-adhesive function: Lp(a) induces VCAM-1/E-selectin via intracellular calcium, mediated by apo(a) and independent of known lipoprotein receptors.","evidence":"HCAEC culture, adhesion molecule measurement, BAPTA/AM chelation, recombinant apo(a) competition, multiple receptor-blocking controls","pmids":["9837867"],"confidence":"Medium","gaps":["The receptor/sensor transducing the calcium signal not identified","Single lab"]},{"year":2015,"claim":"Defined the molecular basis of Lp(a) proinflammatory signaling, showing apo(a)-borne oxidized phospholipids drive IL-8 through CD36/TLR2–MAPK–NF-κB/AP-1, tying a structural cargo to a signaling output.","evidence":"siRNA receptor knockdown, MAPK inhibitors, IL-8 promoter luciferase mutants, enzymatic oxPL removal, LBS-mutant apo(a) in THP-1/U937","pmids":["26474593"],"confidence":"High","gaps":["In vivo relevance of the macrophage pathway not established here","Contribution relative to other oxPL carriers unquantified"]},{"year":1995,"claim":"Revealed an effect on vascular smooth muscle signaling: Lp(a) selectively down-regulates glucocorticoid receptor expression, blunting the antiproliferative action of glucocorticoids.","evidence":"Nuclear GR radioligand binding, GR mRNA Northern blotting, proliferation assays across cell and lipoprotein types","pmids":["7649076"],"confidence":"Medium","gaps":["Receptor/signal mediating GR down-regulation not identified","Single lab"]},{"year":1996,"claim":"Characterized Lp(a)-associated PAF-acetylhydrolase, showing most activity resides on the lipid/apoB core rather than apo(a) and is sensitive to particle oxidation.","evidence":"Density-gradient ultracentrifugation, DTT cleavage, PAF-AH activity and Cu2+-oxidation kinetics","pmids":["8831934"],"confidence":"Medium","gaps":["Physiological consequence of isoform-dependent kinetics unresolved","Single lab"]},{"year":1991,"claim":"Explained the relative oxidation resistance of Lp(a) by attributing its extended lag phase to high sialic acid content, demonstrated by neuraminidase removal and NANA reconstitution.","evidence":"Paired Cu2+ lipid peroxidation of Lp(a) and LDL, neuraminidase treatment, NANA reconstitution, composition analysis","pmids":["1825020"],"confidence":"Medium","gaps":["In vivo relevance of differential oxidation kinetics not addressed","Single lab"]},{"year":1999,"claim":"Linked oxidized Lp(a) to endothelial injury, showing oxLp(a) is more potent than oxLDL at inducing apoptosis via superoxide and high lysophosphatidylcholine content.","evidence":"DNA fragmentation, Annexin V, TUNEL, superoxide measurement, SOD/catalase and DDTC manipulation, lysoPC quantification in HUVECs and rabbit aorta","pmids":["10201010"],"confidence":"Medium","gaps":["Upstream receptor/uptake route for oxLp(a) not defined","Single lab"]},{"year":2015,"claim":"Extended oxLp(a) endothelial signaling to autophagy, mapping a ROS-dependent PARP-1–LKB1–AMPK–mTOR axis.","evidence":"Autophagy and ROS assays, pathway inhibitor and SOD studies, Western blotting in HUVECs","pmids":["26407666"],"confidence":"Medium","gaps":["Single cell type and lab","Functional outcome of autophagy for cell fate not resolved"]},{"year":1999,"claim":"Showed Lp(a) is a negative acute-phase reactant, declining during inflammation through decreased production rather than enhanced catabolism, integrating Lp(a) regulation with systemic inflammatory state.","evidence":"Serial plasma measurements in sepsis/burns patients, apo(a) fragment and urinary apo(a) assays, LPS-challenge mouse clearance study","pmids":["10764684"],"confidence":"Medium","gaps":["Transcriptional/hepatic mechanism of decreased production not defined","Single lab"]},{"year":2017,"claim":"Implicated Lp(a) in calcific aortic valve disease via interaction with autotaxin promoting valve mineralization, extending Lp(a) pathobiology beyond atherothrombosis.","evidence":"Mechanistic claim summarized in a review citing original work","pmids":["28816078"],"confidence":"Low","gaps":["Primary experimental detail not available in this entry","Direct Lp(a)–autotaxin interaction not independently characterized in the timeline"]},{"year":null,"claim":"The molecular identity of the extracellular oxidase that catalyzes covalent Lp(a) assembly, and how it integrates with the intracellular noncovalent assembly step, remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["Oxidase enzyme unidentified","Cofactor required for assembly unknown","Coupling between hepatocyte secretion and extracellular covalent assembly undefined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0008289","term_label":"lipid binding","supporting_discovery_ids":[13,14,20]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[4,12,16]},{"term_id":"GO:0008092","term_label":"cytoskeletal protein binding","supporting_discovery_ids":[10,11]}],"localization":[{"term_id":"GO:0005783","term_label":"endoplasmic reticulum","supporting_discovery_ids":[8]},{"term_id":"GO:0005794","term_label":"Golgi apparatus","supporting_discovery_ids":[8]},{"term_id":"GO:0005768","term_label":"endosome","supporting_discovery_ids":[8]},{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[0,1]},{"term_id":"GO:0031012","term_label":"extracellular matrix","supporting_discovery_ids":[10,11]}],"pathway":[{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[3,8,21]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[12,13,18]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[13,17]}],"complexes":["Lp(a) particle (apo(a)/apoB-100)"],"partners":["APOB","VLDLR","LDLR","CD36","TLR2","PLG"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P08519","full_name":"Apolipoprotein(a)","aliases":[],"length_aa":2040,"mass_kda":226.5,"function":"Apo(a) is the main constituent of lipoprotein(a) (Lp(a)). It has serine proteinase activity and is able of autoproteolysis. Inhibits tissue-type plasminogen activator 1. Lp(a) may be a ligand for megalin/Gp 330","subcellular_location":"","url":"https://www.uniprot.org/uniprotkb/P08519/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/LPA","classification":"Not Classified","n_dependent_lines":37,"n_total_lines":1165,"dependency_fraction":0.03175965665236052},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/LPA","total_profiled":1310},"omim":[{"mim_id":"620871","title":"DNA DAMAGE-INDUCIBLE 1 HOMOLOG 2; DDI2","url":"https://www.omim.org/entry/620871"},{"mim_id":"619590","title":"PHOSPHOLIPID PHOSPHATASE-RELATED PROTEIN 1; PLPPR1","url":"https://www.omim.org/entry/619590"},{"mim_id":"618807","title":"LIPOPROTEIN(a) QUANTITATIVE TRAIT LOCUS; LPAQTL","url":"https://www.omim.org/entry/618807"},{"mim_id":"614796","title":"1-@ACYLGLYCEROL-3-PHOSPHATE O-ACYLTRANSFERASE 5; AGPAT5","url":"https://www.omim.org/entry/614796"},{"mim_id":"614794","title":"1-@ACYLGLYCEROL-3-PHOSPHATE O-ACYLTRANSFERASE 3; AGPAT3","url":"https://www.omim.org/entry/614794"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in some","driving_tissues":[{"tissue":"liver","ntpm":71.8}],"url":"https://www.proteinatlas.org/search/LPA"},"hgnc":{"alias_symbol":["Lp(a)"],"prev_symbol":["LP"]},"alphafold":{"accession":"P08519","domains":[],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P08519","model_url":"https://alphafold.ebi.ac.uk/files/AF-P08519-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P08519-F1-predicted_aligned_error_v6.png","plddt_mean":60.06},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=LPA","jax_strain_url":"https://www.jax.org/strain/search?query=LPA"},"sequence":{"accession":"P08519","fasta_url":"https://rest.uniprot.org/uniprotkb/P08519.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P08519/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P08519"}},"corpus_meta":[{"pmid":"20032323","id":"PMC_20032323","title":"Genetic variants associated with Lp(a) lipoprotein level and coronary disease.","date":"2009","source":"The New England journal of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/20032323","citation_count":1276,"is_preprint":false},{"pmid":"2956279","id":"PMC_2956279","title":"Lp(a) glycoprotein phenotypes. Inheritance and relation to Lp(a)-lipoprotein concentrations in plasma.","date":"1987","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/2956279","citation_count":835,"is_preprint":false},{"pmid":"6219896","id":"PMC_6219896","title":"Protein composition of Lp(a) lipoprotein from human plasma.","date":"1983","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/6219896","citation_count":242,"is_preprint":false},{"pmid":"168455","id":"PMC_168455","title":"Lp(a) lipoprotein: relationship to sinking pre-beta lipoprotein hyperlipoproteinemia, and apolipoprotein B.","date":"1975","source":"Metabolism: clinical and experimental","url":"https://pubmed.ncbi.nlm.nih.gov/168455","citation_count":164,"is_preprint":false},{"pmid":"18356547","id":"PMC_18356547","title":"Enhanced expression of Lp-PLA2 and lysophosphatidylcholine in symptomatic carotid atherosclerotic plaques.","date":"2008","source":"Stroke","url":"https://pubmed.ncbi.nlm.nih.gov/18356547","citation_count":148,"is_preprint":false},{"pmid":"9410893","id":"PMC_9410893","title":"The atherogenic lipoprotein Lp(a) is internalized and degraded in a process mediated by the VLDL receptor.","date":"1997","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/9410893","citation_count":142,"is_preprint":false},{"pmid":"2527286","id":"PMC_2527286","title":"Enzyme-linked immunoassay for Lp[a].","date":"1989","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/2527286","citation_count":132,"is_preprint":false},{"pmid":"1825020","id":"PMC_1825020","title":"Oxidation of lipoprotein Lp(a). A comparison with low-density lipoproteins.","date":"1991","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/1825020","citation_count":127,"is_preprint":false},{"pmid":"15290086","id":"PMC_15290086","title":"Lp(a) lipoprotein and lipids in patients with rheumatoid arthritis: serum levels and relationship to inflammation.","date":"2004","source":"Rheumatology international","url":"https://pubmed.ncbi.nlm.nih.gov/15290086","citation_count":121,"is_preprint":false},{"pmid":"33766265","id":"PMC_33766265","title":"Emerging RNA Therapeutics to Lower Blood Levels of Lp(a): JACC Focus Seminar 2/4.","date":"2021","source":"Journal of the American College of Cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/33766265","citation_count":118,"is_preprint":false},{"pmid":"7757064","id":"PMC_7757064","title":"Sequence polymorphisms in the apo(a) gene associated with specific levels of Lp(a) in plasma.","date":"1995","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/7757064","citation_count":114,"is_preprint":false},{"pmid":"10201010","id":"PMC_10201010","title":"Lp(a) and LDL induce apoptosis in human endothelial cells and in rabbit aorta: role of oxidative stress.","date":"1999","source":"Kidney international","url":"https://pubmed.ncbi.nlm.nih.gov/10201010","citation_count":113,"is_preprint":false},{"pmid":"9837867","id":"PMC_9837867","title":"Expression of adhesion molecules by lp(a): a potential novel mechanism for its atherogenicity.","date":"1998","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/9837867","citation_count":93,"is_preprint":false},{"pmid":"26474593","id":"PMC_26474593","title":"Mechanistic insights into Lp(a)-induced IL-8 expression: a role for oxidized phospholipid modification of apo(a).","date":"2015","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/26474593","citation_count":91,"is_preprint":false},{"pmid":"6277537","id":"PMC_6277537","title":"Lp(a) lipoprotein enters cultured fibroblasts independently of the plasma membrane low density lipoprotein receptor.","date":"1981","source":"Clinical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/6277537","citation_count":88,"is_preprint":false},{"pmid":"35606079","id":"PMC_35606079","title":"Beyond fibrinolysis: The confounding role of Lp(a) in thrombosis.","date":"2022","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/35606079","citation_count":86,"is_preprint":false},{"pmid":"16177824","id":"PMC_16177824","title":"Mediation of Epstein-Barr virus EBNA-LP transcriptional coactivation by Sp100.","date":"2005","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/16177824","citation_count":80,"is_preprint":false},{"pmid":"21955667","id":"PMC_21955667","title":"Antioxidant and inflammatory aspects of lipoprotein-associated phospholipase A₂ (Lp-PLA₂): a review.","date":"2011","source":"Lipids in health and disease","url":"https://pubmed.ncbi.nlm.nih.gov/21955667","citation_count":75,"is_preprint":false},{"pmid":"20600619","id":"PMC_20600619","title":"LP-211 is a brain penetrant selective agonist for the serotonin 5-HT(7) receptor.","date":"2010","source":"Neuroscience letters","url":"https://pubmed.ncbi.nlm.nih.gov/20600619","citation_count":75,"is_preprint":false},{"pmid":"7514505","id":"PMC_7514505","title":"Lp(a): an acute-phase reactant?","date":"1994","source":"Chemistry and physics of lipids","url":"https://pubmed.ncbi.nlm.nih.gov/7514505","citation_count":72,"is_preprint":false},{"pmid":"11963798","id":"PMC_11963798","title":"Lp-PLA2: an emerging biomarker of coronary heart disease.","date":"2002","source":"Expert review of molecular diagnostics","url":"https://pubmed.ncbi.nlm.nih.gov/11963798","citation_count":69,"is_preprint":false},{"pmid":"10590127","id":"PMC_10590127","title":"Sequence and functional analysis of EBNA-LP and EBNA2 proteins from nonhuman primate lymphocryptoviruses.","date":"2000","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/10590127","citation_count":67,"is_preprint":false},{"pmid":"11313151","id":"PMC_11313151","title":"The mouse lp(A3)/Edg7 lysophosphatidic acid receptor gene: genomic structure, chromosomal localization, and expression pattern.","date":"2001","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/11313151","citation_count":62,"is_preprint":false},{"pmid":"26428371","id":"PMC_26428371","title":"EBNA2 and Its Coactivator EBNA-LP.","date":"2015","source":"Current topics in microbiology and immunology","url":"https://pubmed.ncbi.nlm.nih.gov/26428371","citation_count":60,"is_preprint":false},{"pmid":"10484779","id":"PMC_10484779","title":"Molecular basis of congenital lp(a) deficiency: a frequent apo(a) 'null' mutation in caucasians.","date":"1999","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/10484779","citation_count":59,"is_preprint":false},{"pmid":"7667829","id":"PMC_7667829","title":"Interaction of Lp(a) with plasminogen binding sites on cells.","date":"1995","source":"Thrombosis and haemostasis","url":"https://pubmed.ncbi.nlm.nih.gov/7667829","citation_count":56,"is_preprint":false},{"pmid":"24953389","id":"PMC_24953389","title":"Pathophysiological role and clinical significance of lipoprotein-associated phospholipase A₂ (Lp-PLA₂) bound to LDL and HDL.","date":"2014","source":"Current pharmaceutical design","url":"https://pubmed.ncbi.nlm.nih.gov/24953389","citation_count":55,"is_preprint":false},{"pmid":"10764684","id":"PMC_10764684","title":"Major reduction in plasma Lp(a) levels during sepsis and burns.","date":"2000","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/10764684","citation_count":51,"is_preprint":false},{"pmid":"8187248","id":"PMC_8187248","title":"Lp(a) lipoprotein: an overview.","date":"1994","source":"Chemistry and physics of lipids","url":"https://pubmed.ncbi.nlm.nih.gov/8187248","citation_count":50,"is_preprint":false},{"pmid":"9781014","id":"PMC_9781014","title":"Concentrations of the atherogenic Lp(a) are elevated in FH.","date":"1998","source":"European journal of human genetics : EJHG","url":"https://pubmed.ncbi.nlm.nih.gov/9781014","citation_count":49,"is_preprint":false},{"pmid":"11160753","id":"PMC_11160753","title":"EBNA-LP associates with cellular proteins including DNA-PK and HA95.","date":"2001","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/11160753","citation_count":48,"is_preprint":false},{"pmid":"28428482","id":"PMC_28428482","title":"Triglyceride Rich Lipoprotein -LPL-VLDL Receptor and Lp(a)-VLDL Receptor Pathways for Macrophage Foam Cell Formation.","date":"2017","source":"Journal of atherosclerosis and thrombosis","url":"https://pubmed.ncbi.nlm.nih.gov/28428482","citation_count":46,"is_preprint":false},{"pmid":"8831934","id":"PMC_8831934","title":"PAF-acetylhydrolase activity of Lp(a) before and during Cu(2+)-induced oxidative modification in vitro.","date":"1996","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/8831934","citation_count":46,"is_preprint":false},{"pmid":"10323765","id":"PMC_10323765","title":"Proteoglycans contribution to association of Lp(a) and LDL with smooth muscle cell extracellular matrix.","date":"1999","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/10323765","citation_count":46,"is_preprint":false},{"pmid":"37506332","id":"PMC_37506332","title":"LP(a): Structure, Genetics, Associated Cardiovascular Risk, and Emerging Therapeutics.","date":"2023","source":"Annual review of pharmacology and toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/37506332","citation_count":45,"is_preprint":false},{"pmid":"7495343","id":"PMC_7495343","title":"Lp(a) lipoprotein levels as a predictor of risk for thrombogenic events in patients with Behçet's disease.","date":"1995","source":"Annals of the rheumatic diseases","url":"https://pubmed.ncbi.nlm.nih.gov/7495343","citation_count":45,"is_preprint":false},{"pmid":"7749840","id":"PMC_7749840","title":"Lipid and lipoprotein factors associated with variation in Lp(a) density.","date":"1995","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/7749840","citation_count":42,"is_preprint":false},{"pmid":"27346583","id":"PMC_27346583","title":"Oxidized phospholipids and lipoprotein-associated phospholipase A2 as important determinants of Lp(a) functionality and pathophysiological role.","date":"2018","source":"Journal of biomedical research","url":"https://pubmed.ncbi.nlm.nih.gov/27346583","citation_count":41,"is_preprint":false},{"pmid":"16873290","id":"PMC_16873290","title":"Lp-PLA2: a new kid on the block.","date":"2006","source":"Clinical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16873290","citation_count":41,"is_preprint":false},{"pmid":"29427237","id":"PMC_29427237","title":"Differential expression of Lp-PLA2 in obesity and type 2 diabetes and the influence of lipids.","date":"2018","source":"Diabetologia","url":"https://pubmed.ncbi.nlm.nih.gov/29427237","citation_count":41,"is_preprint":false},{"pmid":"34093570","id":"PMC_34093570","title":"Identification of Inflammation-Related Biomarker Lp-PLA2 for Patients With COPD by Comprehensive Analysis.","date":"2021","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/34093570","citation_count":41,"is_preprint":false},{"pmid":"12088177","id":"PMC_12088177","title":"Diagnostic value of CRP and Lp(a) in coronary heart disease.","date":"2002","source":"Acta cardiologica","url":"https://pubmed.ncbi.nlm.nih.gov/12088177","citation_count":40,"is_preprint":false},{"pmid":"27514608","id":"PMC_27514608","title":"Lp(a) and cardiovascular risk: Investigating the hidden side of the moon.","date":"2016","source":"Nutrition, metabolism, and cardiovascular diseases : NMCD","url":"https://pubmed.ncbi.nlm.nih.gov/27514608","citation_count":38,"is_preprint":false},{"pmid":"30859385","id":"PMC_30859385","title":"Prediction of cardiovascular risk by Lp(a) concentrations or genetic variants within the LPA gene region.","date":"2019","source":"Clinical research in cardiology supplements","url":"https://pubmed.ncbi.nlm.nih.gov/30859385","citation_count":38,"is_preprint":false},{"pmid":"1838924","id":"PMC_1838924","title":"Does lipoprotein(a) (Lp(a)) complete with plasminogen in human atherosclerotic lesions and thrombi?","date":"1991","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/1838924","citation_count":38,"is_preprint":false},{"pmid":"8318510","id":"PMC_8318510","title":"Interaction of Lp(a) and of apo(a) with liver cells.","date":"1993","source":"Arteriosclerosis and thrombosis : a journal of vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/8318510","citation_count":38,"is_preprint":false},{"pmid":"1606170","id":"PMC_1606170","title":"Isolation and partial characterization of lipoprotein A-II (LP-A-II) particles of human plasma.","date":"1992","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/1606170","citation_count":38,"is_preprint":false},{"pmid":"38636747","id":"PMC_38636747","title":"Antioxidant and anti-aging activities of Longan crude and purified polysaccharide (LP-A) in nematode Caenorhabditis elegans.","date":"2024","source":"International journal of biological macromolecules","url":"https://pubmed.ncbi.nlm.nih.gov/38636747","citation_count":37,"is_preprint":false},{"pmid":"26407666","id":"PMC_26407666","title":"Ox-Lp(a) transiently induces HUVEC autophagy via an ROS-dependent PAPR-1-LKB1-AMPK-mTOR pathway.","date":"2015","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/26407666","citation_count":35,"is_preprint":false},{"pmid":"36066255","id":"PMC_36066255","title":"Exosome-Loaded Pro-efferocytic Vascular Stent with Lp-PLA2-Triggered Release for Preventing In-Stent Restenosis.","date":"2022","source":"ACS nano","url":"https://pubmed.ncbi.nlm.nih.gov/36066255","citation_count":34,"is_preprint":false},{"pmid":"11948806","id":"PMC_11948806","title":"Immunohistological localization of the myelinating cell-specific receptor LP(A1).","date":"2002","source":"Glia","url":"https://pubmed.ncbi.nlm.nih.gov/11948806","citation_count":33,"is_preprint":false},{"pmid":"10588951","id":"PMC_10588951","title":"Preparation of a stable fresh frozen primary lipoprotein[a] (Lp[a]) standard.","date":"1999","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/10588951","citation_count":30,"is_preprint":false},{"pmid":"36066785","id":"PMC_36066785","title":"Lp(a): a New Pathway to Target?","date":"2022","source":"Current atherosclerosis reports","url":"https://pubmed.ncbi.nlm.nih.gov/36066785","citation_count":29,"is_preprint":false},{"pmid":"31043469","id":"PMC_31043469","title":"ApoB, small-dense LDL-C, Lp(a), LpPLA2 activity, and cognitive change.","date":"2019","source":"Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/31043469","citation_count":29,"is_preprint":false},{"pmid":"29096833","id":"PMC_29096833","title":"Specific Lp(a) apheresis: A tool to prove lipoprotein(a) atherogenicity.","date":"2017","source":"Atherosclerosis. Supplements","url":"https://pubmed.ncbi.nlm.nih.gov/29096833","citation_count":28,"is_preprint":false},{"pmid":"12810066","id":"PMC_12810066","title":"Identification of AMSH-LP containing a Jab1/MPN domain metalloenzyme motif.","date":"2003","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/12810066","citation_count":28,"is_preprint":false},{"pmid":"16712749","id":"PMC_16712749","title":"[Inflammation, atherosclerosis and cardiovascular disease risk: PAPP-A, Lp-PLA2 and cystatin C. New insights or redundant information?].","date":"2006","source":"Revista espanola de cardiologia","url":"https://pubmed.ncbi.nlm.nih.gov/16712749","citation_count":28,"is_preprint":false},{"pmid":"27940953","id":"PMC_27940953","title":"Genetic invalidation of Lp-PLA2 as a therapeutic target: Large-scale study of five functional Lp-PLA2-lowering alleles.","date":"2016","source":"European journal of preventive cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/27940953","citation_count":27,"is_preprint":false},{"pmid":"2146124","id":"PMC_2146124","title":"Is the atherogenicity of Lp(a) caused by its reactivity with proteoglycans?","date":"1990","source":"European heart journal","url":"https://pubmed.ncbi.nlm.nih.gov/2146124","citation_count":26,"is_preprint":false},{"pmid":"16438975","id":"PMC_16438975","title":"Lp-PLA2 activity and PLA2G7 A379V genotype in patients with diabetes mellitus.","date":"2006","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/16438975","citation_count":26,"is_preprint":false},{"pmid":"32927635","id":"PMC_32927635","title":"Characterization of LP-Z Lipoprotein Particles and Quantification in Subjects with Liver Disease Using a Newly Developed NMR-Based Assay.","date":"2020","source":"Journal of clinical medicine","url":"https://pubmed.ncbi.nlm.nih.gov/32927635","citation_count":26,"is_preprint":false},{"pmid":"24328921","id":"PMC_24328921","title":"Lp-PLA2 is associated with structural valve degeneration of bioprostheses.","date":"2013","source":"European journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/24328921","citation_count":26,"is_preprint":false},{"pmid":"31371270","id":"PMC_31371270","title":"Individuals with familial hypercholesterolemia and cardiovascular events have higher circulating Lp(a) levels.","date":"2019","source":"Journal of clinical lipidology","url":"https://pubmed.ncbi.nlm.nih.gov/31371270","citation_count":25,"is_preprint":false},{"pmid":"16267501","id":"PMC_16267501","title":"Genetics of the Lp(a)/apo(a) system in an autochthonous Black African population from the Gabon.","date":"2006","source":"European journal of human genetics : EJHG","url":"https://pubmed.ncbi.nlm.nih.gov/16267501","citation_count":25,"is_preprint":false},{"pmid":"31350625","id":"PMC_31350625","title":"Looking at Lp(a) and Related Cardiovascular Risk: from Scientific Evidence and Clinical Practice.","date":"2019","source":"Current atherosclerosis reports","url":"https://pubmed.ncbi.nlm.nih.gov/31350625","citation_count":24,"is_preprint":false},{"pmid":"19064127","id":"PMC_19064127","title":"Metalloproteases 2 and 9, Lp-PLA(2) and lipoprotein profile in coronary patients.","date":"2009","source":"Archives of medical research","url":"https://pubmed.ncbi.nlm.nih.gov/19064127","citation_count":24,"is_preprint":false},{"pmid":"16893192","id":"PMC_16893192","title":"Catalysis of covalent Lp(a) assembly: evidence for an extracellular enzyme activity that enhances disulfide bond formation.","date":"2006","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16893192","citation_count":23,"is_preprint":false},{"pmid":"20425268","id":"PMC_20425268","title":"Lp-PLA2: A new target for statin therapy.","date":"2010","source":"Current atherosclerosis reports","url":"https://pubmed.ncbi.nlm.nih.gov/20425268","citation_count":22,"is_preprint":false},{"pmid":"9520125","id":"PMC_9520125","title":"Metabolism of Lp(a): assembly and excretion.","date":"1997","source":"Clinical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/9520125","citation_count":22,"is_preprint":false},{"pmid":"35045727","id":"PMC_35045727","title":"Apo(a) and ApoB Interact Noncovalently Within Hepatocytes: Implications for Regulation of Lp(a) Levels by Modulation of ApoB Secretion.","date":"2022","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/35045727","citation_count":21,"is_preprint":false},{"pmid":"18000162","id":"PMC_18000162","title":"Effects of atorvastatin on Lp(a) and lipoprotein profiles in hemodialysis patients.","date":"2007","source":"The Annals of pharmacotherapy","url":"https://pubmed.ncbi.nlm.nih.gov/18000162","citation_count":21,"is_preprint":false},{"pmid":"33872986","id":"PMC_33872986","title":"Prevalence and influence of LPA gene variants and isoform size on the Lp(a)-lowering effect of pelacarsen.","date":"2021","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/33872986","citation_count":21,"is_preprint":false},{"pmid":"1828399","id":"PMC_1828399","title":"Lp(a) as a marker for coronary heart disease risk.","date":"1991","source":"Clinical cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/1828399","citation_count":20,"is_preprint":false},{"pmid":"28300647","id":"PMC_28300647","title":"Heter-LP: A heterogeneous label propagation algorithm and its application in drug repositioning.","date":"2017","source":"Journal of biomedical informatics","url":"https://pubmed.ncbi.nlm.nih.gov/28300647","citation_count":20,"is_preprint":false},{"pmid":"41091599","id":"PMC_41091599","title":"Antibody evasion and receptor binding of SARS-CoV-2 LP.8.1.1, NB.1.8.1, XFG, and related subvariants.","date":"2025","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/41091599","citation_count":19,"is_preprint":false},{"pmid":"35408941","id":"PMC_35408941","title":"Lp(a) and the Risk for Cardiovascular Disease: Focus on the Lp(a) Paradox in Diabetes Mellitus.","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/35408941","citation_count":19,"is_preprint":false},{"pmid":"8828980","id":"PMC_8828980","title":"How often has Lp(a) evolved?","date":"1996","source":"Clinical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/8828980","citation_count":19,"is_preprint":false},{"pmid":"22074435","id":"PMC_22074435","title":"Therapeutic modulation of lipoprotein-associated phospholipase A2 (Lp-PLA2).","date":"2011","source":"Current pharmaceutical design","url":"https://pubmed.ncbi.nlm.nih.gov/22074435","citation_count":19,"is_preprint":false},{"pmid":"27486450","id":"PMC_27486450","title":"The Lp_3561 and Lp_3562 Enzymes Support a Functional Divergence Process in the Lipase/Esterase Toolkit from Lactobacillus plantarum.","date":"2016","source":"Frontiers in microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/27486450","citation_count":19,"is_preprint":false},{"pmid":"37668953","id":"PMC_37668953","title":"Treatment of Lp(a): Is It the Future or Are We Ready Today?","date":"2023","source":"Current atherosclerosis reports","url":"https://pubmed.ncbi.nlm.nih.gov/37668953","citation_count":18,"is_preprint":false},{"pmid":"28816078","id":"PMC_28816078","title":"Pathobiology of Lp(a) in calcific aortic valve disease.","date":"2017","source":"Expert review of cardiovascular therapy","url":"https://pubmed.ncbi.nlm.nih.gov/28816078","citation_count":18,"is_preprint":false},{"pmid":"10594806","id":"PMC_10594806","title":"Plasma and Lp(a)-associated PAF-acetylhydrolase activity in uremic patients undergoing different dialysis procedures.","date":"1999","source":"Kidney international","url":"https://pubmed.ncbi.nlm.nih.gov/10594806","citation_count":18,"is_preprint":false},{"pmid":"1535652","id":"PMC_1535652","title":"Genetic basis and pathophysiological implications of high plasma Lp(a) levels.","date":"1992","source":"Journal of internal medicine","url":"https://pubmed.ncbi.nlm.nih.gov/1535652","citation_count":17,"is_preprint":false},{"pmid":"37128734","id":"PMC_37128734","title":"Developing an SI-traceable Lp(a) reference measurement system: a pilgrimage to selective and accurate apo(a) quantification.","date":"2023","source":"Critical reviews in clinical laboratory sciences","url":"https://pubmed.ncbi.nlm.nih.gov/37128734","citation_count":17,"is_preprint":false},{"pmid":"18844582","id":"PMC_18844582","title":"Regulation of Sp100A subnuclear localization and transcriptional function by EBNA-LP and interferon.","date":"2008","source":"Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research","url":"https://pubmed.ncbi.nlm.nih.gov/18844582","citation_count":17,"is_preprint":false},{"pmid":"40389600","id":"PMC_40389600","title":"Targeting Lp-PLA2 inhibits profibrotic monocyte-derived macrophages in silicosis through restoring cardiolipin-mediated mitophagy.","date":"2025","source":"Cellular & molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/40389600","citation_count":16,"is_preprint":false},{"pmid":"8187227","id":"PMC_8187227","title":"The relationship between infant and parent Lp(a) levels.","date":"1994","source":"Chemistry and physics of lipids","url":"https://pubmed.ncbi.nlm.nih.gov/8187227","citation_count":16,"is_preprint":false},{"pmid":"22634007","id":"PMC_22634007","title":"Inhibition of Lp(a)-induced functional impairment of endothelial cells and endothelial progenitor cells by hepatocyte growth factor.","date":"2012","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/22634007","citation_count":16,"is_preprint":false},{"pmid":"33663862","id":"PMC_33663862","title":"Lactobacillus plantarum GB LP-1 as a direct-fed microbial for neonatal calves.","date":"2021","source":"Journal of dairy science","url":"https://pubmed.ncbi.nlm.nih.gov/33663862","citation_count":16,"is_preprint":false},{"pmid":"17133260","id":"PMC_17133260","title":"Multiple QTL influence the serum Lp(a) concentration: a genome-wide linkage screen in the PROCARDIS study.","date":"2006","source":"European journal of human genetics : EJHG","url":"https://pubmed.ncbi.nlm.nih.gov/17133260","citation_count":16,"is_preprint":false},{"pmid":"2967739","id":"PMC_2967739","title":"Heterogeneity of lipoprotein Lp(a) and apolipoprotein(a).","date":"1988","source":"Clinical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/2967739","citation_count":16,"is_preprint":false},{"pmid":"20623998","id":"PMC_20623998","title":"Human SepSecS or SLA/LP: selenocysteine formation and autoimmune hepatitis.","date":"2010","source":"Biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20623998","citation_count":15,"is_preprint":false},{"pmid":"37993464","id":"PMC_37993464","title":"Structure of the N-RNA/P interface indicates mode of L/P recruitment to the nucleocapsid of human metapneumovirus.","date":"2023","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/37993464","citation_count":15,"is_preprint":false},{"pmid":"39627254","id":"PMC_39627254","title":"Cryo-EM structure of Nipah virus L-P polymerase complex.","date":"2024","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/39627254","citation_count":14,"is_preprint":false},{"pmid":"7649076","id":"PMC_7649076","title":"Glucocorticoid receptor expression is down-regulated by Lp(a) lipoprotein in vascular smooth muscle cells.","date":"1995","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/7649076","citation_count":14,"is_preprint":false},{"pmid":"31861087","id":"PMC_31861087","title":"Homburgvirus LP-018 Has a Unique Ability to Infect Phage-Resistant Listeria monocytogenes.","date":"2019","source":"Viruses","url":"https://pubmed.ncbi.nlm.nih.gov/31861087","citation_count":14,"is_preprint":false},{"pmid":"36412196","id":"PMC_36412196","title":"Lp-PLA2 (Lipoprotein-Associated Phospholipase A2) Deficiency Lowers Cholesterol Levels and Protects Against Atherosclerosis in Rabbits.","date":"2022","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/36412196","citation_count":13,"is_preprint":false},{"pmid":"15527420","id":"PMC_15527420","title":"A novel human complement-related protein, C1r-like protease (C1r-LP), specifically cleaves pro-C1s.","date":"2005","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/15527420","citation_count":13,"is_preprint":false},{"pmid":"40781022","id":"PMC_40781022","title":"Pelacarsen: Mechanism of action and Lp(a)-lowering effect.","date":"2025","source":"Journal of clinical lipidology","url":"https://pubmed.ncbi.nlm.nih.gov/40781022","citation_count":12,"is_preprint":false},{"pmid":"40430570","id":"PMC_40430570","title":"Lp(a)-Lowering Agents in Development: A New Era in Tackling the Burden of Cardiovascular Risk?","date":"2025","source":"Pharmaceuticals (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/40430570","citation_count":12,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":55535,"output_tokens":6948,"usd":0.135412,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":15883,"output_tokens":6477,"usd":0.12067,"stage2_stop_reason":"end_turn"},"total_usd":0.256082,"stage1_batch_id":"msgbatch_01BbTCMyrRPyhtEq6b1MdwCN","stage2_batch_id":"msgbatch_011dEed5bbxYvTAaQWKJevxu","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1983,\n      \"finding\": \"Lp(a) lipoprotein contains two polypeptide chains: apolipoprotein B-100 (identical to LDL apoB) and a high-molecular-weight glycoprotein (~350 kDa) carrying the specific Lp(a) immunoreactivity. These two components are linked by disulfide bonds in the native lipoprotein, as the unreduced delipidized protein moiety runs as a single ~700 kDa band on SDS-PAGE.\",\n      \"method\": \"SDS-polyacrylamide gel electrophoresis under reducing and non-reducing conditions, immunochemical analysis, periodate-Schiff staining\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct biochemical reconstitution/characterization with multiple orthogonal methods (gel electrophoresis, immunoprecipitation, reducing vs non-reducing conditions), foundational structural result independently confirmed by later work\",\n      \"pmids\": [\"6219896\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1987,\n      \"finding\": \"Lp(a) glycoprotein (apo(a)) exhibits inter- and intraindividual size heterogeneity (apparent MW ~400,000–700,000 Da), and phenotypic differences between apo(a) isoforms do not reside in the sialic acid moiety (neuraminidase treatment does not abolish size differences). Family studies indicate phenotypes are controlled by a series of autosomal alleles at a single locus, and isoform size is inversely associated with plasma Lp(a) concentration.\",\n      \"method\": \"SDS-gel electrophoresis under reducing conditions, immunoblotting with anti-Lp(a) serum, neuraminidase treatment, family studies\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — direct biochemical characterization combined with enzymatic treatment and family genetic analysis; foundational finding replicated across subsequent studies\",\n      \"pmids\": [\"2956279\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1981,\n      \"finding\": \"Lp(a) lipoprotein enters cultured fibroblasts independently of the LDL receptor: processing of 125I-Lp(a) was not saturated at high concentrations, was largely receptor-independent (only slightly higher in normal vs. receptor-negative cells), and Lp(a) did not compete with 125I-LDL for receptor-mediated fibroblast association, although it inhibited LDL degradation in a time-dependent manner.\",\n      \"method\": \"125I-labeled ligand binding and degradation assays in fibroblasts from normal, FH heterozygous, and LDL receptor-negative FH homozygous subjects\",\n      \"journal\": \"Clinical genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct receptor-ligand assay with genetically defined receptor-deficient cells; clean negative result for LDL receptor involvement, replicated concept in multiple later studies\",\n      \"pmids\": [\"6277537\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"The VLDL receptor mediates endocytosis and lysosomal degradation of Lp(a). Fibroblasts expressing human VLDL receptor catabolize Lp(a); receptor-deficient fibroblasts do not. Antibodies against VLDL receptor and RAP (a receptor antagonist) block Lp(a) degradation. Catabolism is inhibited by apolipoprotein(a) but not by LDL or anti-apoB antibodies, indicating that apo(a) mediates Lp(a) binding to the VLDL receptor. In vivo, Lp(a) clearance is delayed in VLDL receptor-deficient mice.\",\n      \"method\": \"Receptor-expressing vs. receptor-deficient fibroblast assays, antibody and RAP inhibition, in vivo mouse clearance studies, immunohistochemistry of human atherosclerotic lesions\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (cell-based catabolism, antibody inhibition, RAP competition, in vivo mouse model), consistent results across assays\",\n      \"pmids\": [\"9410893\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"Lp(a) interacts directly with plasminogen binding sites on monocytoid U937 cells and endothelial cells in a time-dependent, specific, saturable, divalent ion-independent, and temperature-sensitive manner with affinity similar to plasminogen (Kd ~1–3 μM), but binds to ~10-fold fewer sites. Gangliosides and cell-surface proteins with C-terminal lysyl residues (including enolase) inhibit Lp(a) binding, indicating shared plasminogen receptor sites.\",\n      \"method\": \"Binding assays with radiolabeled Lp(a) on U937 and endothelial cells; competitive inhibition with gangliosides, enolase, and lysine analogs; saturation binding kinetics\",\n      \"journal\": \"Thrombosis and haemostasis\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — quantitative binding assays with Kd determination, multiple competitive inhibitors tested, two cell types used\",\n      \"pmids\": [\"7667829\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"A G→A substitution at the +1 donor splice site of the apo(a) kringle IV type 8 intron occurs in ~6% of Caucasians and causes congenital Lp(a) deficiency. This mutation leads to alternative splicing producing a truncated apo(a). The truncated apo(a) is secreted but cannot form the covalent Lp(a) complex (disulfide-linked apo(a)/apoB-100 complex), resulting in rapid degradation of free apo(a) in plasma.\",\n      \"method\": \"RT-PCR of apo(a) illegitimate transcription, expression of alternatively spliced cDNA in HepG2 cells, immunoprecipitation of plasma apo(a)\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — splice site mutation characterized by RT-PCR, functional consequence established by cell expression system, plasma protein analysis in homozygotes; multiple orthogonal methods in one study\",\n      \"pmids\": [\"10484779\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Cultured human hepatoma cells secrete an extracellular oxidase activity that dramatically enhances the rate of covalent (disulfide bond) Lp(a) assembly. This activity is heat-sensitive and protein-based (retained after ultrafiltration >5 kDa), requires a small-molecule cofactor (lost upon dialysis), and exhibits a ping-pong reaction mechanism kinetically analogous to protein disulfide isomerase. Protein disulfide isomerase itself was ruled out as the responsible enzyme.\",\n      \"method\": \"In vitro Lp(a) assembly assay with hepatoma cell-conditioned medium, heat inactivation, ultrafiltration, dialysis, kinetic analysis (Km, Vmax, rectangular hyperbola fitting)\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro biochemical assay with multiple mechanistic controls and kinetic characterization; single lab, identity of the oxidase not established\",\n      \"pmids\": [\"16893192\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"Lp(a) assembly occurs via a two-step mechanism: (1) noncovalent interactions between apo(a) kringle domains (particularly T-6 and T-7) and circulating LDL, followed by (2) formation of a single disulfide bridge to stabilize the Lp(a) complex. Circulating Lp(a) interacts with kidney cells, where a collagenase-type protease cleaves the N-terminal ~2/3–3/4 of apo(a), with apo(a) fragments found in urine. The core Lp(a) particle is subsequently cleared by the liver.\",\n      \"method\": \"Biochemical analysis of Lp(a) assembly intermediates, identification of apo(a) fragments in urine, in vitro binding studies with kringle domain variants\",\n      \"journal\": \"Clinical genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mechanistic model supported by biochemical data from same lab; some elements inferred rather than directly demonstrated in single paper\",\n      \"pmids\": [\"9520125\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Apo(a) and apoB interact noncovalently within hepatocytes before Lp(a) is secreted. Noncovalent apo(a)/apoB complexes (but not covalent ones) are present in cell lysates. Apo(a) and apoB colocalize in the ER, trans-Golgi, and early endosomes. The noncovalent interaction (mediated by lysine-binding sites 7 and 8 of apo(a)) is required for coupling of apo(a) and Lp(a)-apoB secretion: PCSK9 treatment enhances and lomitapide reduces apo(a) secretion in a manner dependent on this interaction; siRNA knockdown of APOB reduces apo(a) secretion.\",\n      \"method\": \"Co-immunoprecipitation, co-immunofluorescence, proximity ligation assay, pulse-chase metabolic labeling, siRNA knockdown, pharmacological manipulation (PCSK9, lomitapide) in human hepatocellular carcinoma cells expressing wild-type and LBS-mutant 17K apo(a)\",\n      \"journal\": \"Arteriosclerosis, thrombosis, and vascular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (Co-IP, co-IF, PLA, pulse-chase), genetic and pharmacological perturbations, clear mechanistic readouts in a single rigorous study\",\n      \"pmids\": [\"35045727\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"Lp(a) binding to hepatoma cells (HepG2) is predominantly of low affinity and non-saturable (unlike LDL which shows saturable high-affinity binding). Preincubation with Lp(a) or free apo(a) for 48–72 h paradoxically increases subsequent 125I-LDL binding (>2-fold) through a mechanism not involving the LDL receptor (not blocked by anti-LDL receptor antibodies). Coincubation with LDL significantly increases Lp(a) degradation by HepG2 cells, suggesting 'hitchhiking' uptake.\",\n      \"method\": \"Radioligand binding assays with 125I-LDL and 125I-Lp(a) in HepG2 and Hep3B cells, antibody inhibition, preincubation experiments\",\n      \"journal\": \"Arteriosclerosis and thrombosis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — quantitative binding assays with receptor blocking, two hepatoma cell lines tested; single lab\",\n      \"pmids\": [\"8318510\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Chondroitin sulfate proteoglycans in smooth muscle cell extracellular matrix bind both Lp(a) and LDL with high affinity. Lp(a) pre-bound to matrix increases subsequent LDL binding 2–3-fold, with the additional LDL held predominantly by strong non-ionic associations (vs. ~50% ionic for LDL-pretreated matrix), providing a mechanism for cooperative lipoprotein accumulation in arterial lesions.\",\n      \"method\": \"Radioligand binding assays with cultured human arterial smooth muscle cell matrix, chondroitinase/proteoglycan analysis, binding affinity measurements\",\n      \"journal\": \"Arteriosclerosis, thrombosis, and vascular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct binding assays with matrix components identified; enzymatic characterization of interaction type; single lab\",\n      \"pmids\": [\"10323765\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1990,\n      \"finding\": \"Lp(a) forms complexes with glycosaminoglycans (GAG) and proteoglycans (PG) from human aorta with a higher GAG/lipoprotein ratio than LDL. The Lp(a) lacking apo(a) (Lpa-) shows intermediate reactivity between Lp(a) and LDL, indicating apo(a) contributes to but is not solely responsible for the enhanced proteoglycan binding. Lp(a)-glycan complexes incubated with mouse peritoneal macrophages cause cholesteryl ester accumulation and foam cell formation, with the degree of accumulation correlating with proteoglycan reactivity.\",\n      \"method\": \"In vitro complex formation assays with isolated GAG/PG and lipoproteins, macrophage incubation with lipoglycan complexes, cholesterol ester measurement\",\n      \"journal\": \"European heart journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct biochemical binding assays with apo(a)-depleted particles as control, functional foam cell readout; single lab\",\n      \"pmids\": [\"2146124\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Lp(a) stimulates expression of VCAM-1 and E-selectin in cultured human coronary artery endothelial cells (HCAEC) via a rise in intracellular free calcium. This effect is blocked by the intracellular calcium chelator BAPTA/AM. Recombinant apo(a) competes with Lp(a) and attenuates adhesion molecule expression, indicating apo(a) mediates this effect. The LDL receptor, VLDL receptor (RAP-insensitive), LDL receptor-related protein, cell-surface proteoglycans, and plasminogen receptors are not involved in this Lp(a)-induced adhesion molecule production.\",\n      \"method\": \"Cell culture with human coronary artery endothelial cells, VCAM-1/E-selectin protein measurement, intracellular calcium chelation (BAPTA/AM), competitive inhibition with recombinant apo(a), antibody/enzyme blocking of candidate receptors\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple receptor-blocking experiments, calcium-dependence established pharmacologically, recombinant apo(a) competition; single lab\",\n      \"pmids\": [\"9837867\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Recombinant apo(a) containing 17 kringle IV domains induces IL-8 mRNA and protein expression in THP-1 and U937 macrophages via oxidized phospholipids (oxPL) carried on apo(a). Mutation of the lysine-binding site in kringle IV type 10 abolishes oxPL on apo(a) and blunts IL-8 induction. Enzymatic removal of oxPL from apo(a) significantly reduces this effect. The effect is mediated through CD36 and TLR2 receptors, downstream MAPK signaling (JNK and ERK1/2), and requires both NF-κB and AP-1 binding sites in the IL-8 promoter.\",\n      \"method\": \"siRNA receptor knockdown, MAPK inhibitors, luciferase reporter gene assays with IL-8 promoter mutants, enzymatic oxPL removal, trypsin digestion, LBS-mutant apo(a) in macrophage cell lines\",\n      \"journal\": \"Journal of lipid research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (siRNA, pharmacological inhibition, promoter mutagenesis, enzymatic modification of ligand), two macrophage cell lines, clear mechanistic pathway defined in one study\",\n      \"pmids\": [\"26474593\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"PAF-acetylhydrolase (PAF-AH) activity is associated with Lp(a) particles in human plasma. Removal of apo(a) from Lp(a) by reductive cleavage with DTT releases only ~15% of total PAF-AH activity, indicating that most PAF-AH is associated with the lipid/apoB core of Lp(a) rather than with apo(a) itself. Kinetic constants (Km, Vmax) differ significantly between small and large apo(a) isoforms. During Cu2+-induced Lp(a) oxidation, PAF-AH Vmax decreases significantly and extensive phosphatidylcholine hydrolysis to lyso-PC occurs.\",\n      \"method\": \"Density gradient ultracentrifugation, DTT reductive cleavage, PAF-AH activity assay, Cu2+-induced oxidation kinetics, lipid analysis by phospholipid assay\",\n      \"journal\": \"Atherosclerosis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — enzymatic activity measured directly on isolated Lp(a) with apo(a) removal control; kinetic characterization across isoforms; single lab\",\n      \"pmids\": [\"8831934\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1991,\n      \"finding\": \"Lp(a) is oxidized by Cu2+ more slowly than LDL from the same donor (1.2–2.4-fold longer lag phase). The extended lag phase of Lp(a) is attributable to its higher sialic acid (NANA) content: neuraminidase treatment drastically shortens the Lp(a) lag phase, and re-supplementation with NANA at physiological concentrations restores it. LDL lag phase is not significantly affected by neuraminidase.\",\n      \"method\": \"Paired Cu2+-induced lipid peroxidation assays on isolated Lp(a) and LDL, neuraminidase treatment, NANA reconstitution, fatty acid and antioxidant composition analysis\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — in vitro biochemical assay with enzymatic treatment and rescue experiment; paired samples from seven donors; single lab\",\n      \"pmids\": [\"1825020\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"Lp(a) down-regulates glucocorticoid receptor (GR) gene expression and nuclear GR protein levels in human and rat vascular smooth muscle cells (SMC), but not in rat endothelial cells. GR mRNA decreases to 23% of control after 12 h Lp(a) treatment; nuclear GR protein falls to 55% after 48 h. LDL, VLDL, and HDL have no effect on GR in SMC. As a functional consequence, the antiproliferative effect of glucocorticoids on SMC is blunted by Lp(a) exposure.\",\n      \"method\": \"Radioligand binding assay for nuclear GR, Northern blotting for GR mRNA, cell proliferation assay, comparison across lipoprotein types and cell types\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mRNA and protein measured with functional proliferation readout; cell-type and lipoprotein-type specificity controls included; single lab\",\n      \"pmids\": [\"7649076\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Lp(a) behaves as a negative acute-phase reactant: plasma Lp(a) concentrations decline abruptly and transiently during sepsis and major burns, inversely mirroring CRP levels and paralleling LDL-C changes. This decline is not accompanied by increases in plasma apo(a) fragments or urinary apo(a), suggesting decreased production rather than increased degradation/shedding. Mouse turnover studies show that LPS treatment retards Lp(a) clearance, indicating that the reduction is not due to enhanced catabolism.\",\n      \"method\": \"Serial plasma measurements in ICU patients (sepsis, burns), apo(a) fragment immunoassay, urinary apo(a) measurement, mouse Lp(a) clearance study with LPS challenge\",\n      \"journal\": \"Arteriosclerosis, thrombosis, and vascular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — human clinical serial measurements combined with mechanistic mouse clearance study; multiple measurement approaches; single lab\",\n      \"pmids\": [\"10764684\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Oxidized Lp(a) (oxLp(a)) induces autophagy in human umbilical vein endothelial cells (HUVECs) via a reactive oxygen species (ROS)-dependent mechanism. The PARP-1–LKB1–AMPK–mTOR and LKB1–AMPK–mTOR signaling pathways mediate this autophagic response. Superoxide dismutase (antioxidant) inhibits oxLp(a)-induced autophagy, confirming ROS dependence.\",\n      \"method\": \"Autophagy assays in HUVECs, ROS measurement, pathway inhibitor studies (PARP-1, LKB1, AMPK, mTOR), SOD treatment, Western blotting for pathway components\",\n      \"journal\": \"Atherosclerosis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple pathway components probed with functional readout; single lab, single cell type\",\n      \"pmids\": [\"26407666\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Autotaxin (ATX), a lysophospholipase D, interacts with Lp(a) and promotes mineralization of the aortic valve, linking Lp(a) to calcific aortic valve disease (CAVD) pathobiology.\",\n      \"method\": \"Referenced as recent mechanistic data in review; original experimental work cited within the review paper\",\n      \"journal\": \"Expert review of cardiovascular therapy\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — mechanistic claim presented in a review without full experimental detail available in this abstract; original supporting experiment not directly described\",\n      \"pmids\": [\"28816078\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Lp(a) induces apoptosis in human umbilical vein endothelial cells (HUVECs) and rabbit aorta, with oxidized Lp(a) (oxLp(a)) being more potent than oxLDL. oxLp(a) stimulates superoxide (O2-) formation in HUVECs (356% increase) and rabbit aorta (294% increase). Apoptosis induction by oxLp(a) involves O2- as a mediator: it is enhanced by the SOD inhibitor DDTC and blunted by SOD and catalase. Lysophosphatidylcholine content is 7-fold higher in oxLp(a) vs. native Lp(a).\",\n      \"method\": \"DNA fragmentation assay, Annexin V assay, TUNEL staining, O2- measurement, SOD/catalase treatment, SOD inhibitor (DDTC), lysoPC quantification in HUVECs and rabbit aorta segments\",\n      \"journal\": \"Kidney international\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — two cell/tissue systems, pharmacological ROS manipulation with both enhancer and inhibitor controls, multiple apoptosis assays; single lab\",\n      \"pmids\": [\"10201010\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Elevated Lp(a) concentrations in patients with familial hypercholesterolemia (FH) are due to an effect of the LDL receptor deficiency on Lp(a) metabolism, independent of apo(a) genotype. Sib-pair analysis of siblings identical-by-descent at the apo(a) locus but differing in LDLR mutation status shows significantly higher Lp(a) in FH siblings, establishing a quantitative genetic interaction between LDLR status and Lp(a) levels.\",\n      \"method\": \"Sib-pair genetic analysis with IBD determination at apo(a) locus, LDLR mutation genotyping, Lp(a) plasma measurement in 367 family members of 60 index patients\",\n      \"journal\": \"European journal of human genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis by sib-pair design controlling for apo(a) genotype; large family-based study; single analysis\",\n      \"pmids\": [\"9781014\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"Lp(a) is a disulfide-linked complex of apolipoprotein B-100 and the plasminogen-homologous glycoprotein apo(a), assembled via a two-step process in which noncovalent apo(a)/apoB interactions occur intracellularly within hepatocytes (in the ER and Golgi) before an extracellular oxidase activity catalyzes covalent disulfide bond formation; plasma levels are determined primarily by the LPA locus (apo(a) isoform size inversely correlating with concentration), modulated by LDLR status; the particle is catabolized via the VLDL receptor (mediated by apo(a)) and not via the classical LDL receptor; apo(a)'s oxidized phospholipid (oxPL) cargo drives proinflammatory signaling in macrophages through CD36/TLR2–MAPK–NF-κB/AP-1 pathways, while Lp(a) also promotes endothelial dysfunction via calcium-dependent VCAM-1/E-selectin induction, binds plasminogen receptors on cell surfaces to compete with plasminogen activation, accumulates in arterial extracellular matrix through chondroitin sulfate proteoglycan interactions, and down-regulates glucocorticoid receptor expression in vascular smooth muscle cells.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"LPA encodes apolipoprotein(a) (apo(a)), a plasminogen-homologous, kringle-rich glycoprotein that assembles with apolipoprotein B-100 to form the lipoprotein particle Lp(a), a determinant of atherothrombotic and vascular pathobiology [#0, #1]. The native particle is a disulfide-linked complex of apoB-100 and a ~350 kDa apo(a) glycoprotein that displays genetically determined size heterogeneity, with isoform size inversely correlating with plasma concentration and the phenotype controlled by a series of autosomal alleles at a single locus [#0, #1]. Assembly is a two-step process: apo(a) and apoB first associate noncovalently through apo(a) lysine-binding sites 7 and 8 inside hepatocytes, where the two proteins colocalize in the ER, trans-Golgi, and early endosomes, and this interaction is required for coupled secretion of both chains [#7, #8]; covalent disulfide bond formation is subsequently accelerated by a secreted, cofactor-dependent extracellular hepatoma oxidase activity kinetically analogous to but distinct from protein disulfide isomerase [#6]. A splice-site mutation in the apo(a) kringle IV type 8 intron produces a truncated apo(a) that is secreted but cannot form the covalent complex and is rapidly degraded, causing congenital Lp(a) deficiency [#5]. Lp(a) is catabolized via the VLDL receptor through apo(a)-mediated binding rather than the classical LDL receptor, while LDL receptor status nonetheless modulates plasma Lp(a) levels [#2, #3, #21]. Functionally, apo(a) engages cell-surface plasminogen receptor sites carrying C-terminal lysines, competing with plasminogen [#4]; its oxidized-phospholipid cargo drives proinflammatory IL-8 induction in macrophages through CD36/TLR2–MAPK–NF-\\u03baB/AP-1 signaling [#13]; and Lp(a) promotes endothelial VCAM-1/E-selectin expression via a calcium-dependent, receptor-independent mechanism [#12]. Lp(a) accumulates in arterial extracellular matrix through chondroitin sulfate proteoglycan and glycosaminoglycan interactions that promote foam cell formation [#10, #11], down-regulates glucocorticoid receptor expression in vascular smooth muscle cells [#16], and in its oxidized form drives endothelial apoptosis and autophagy through ROS-dependent pathways [#18, #20].\",\n  \"teleology\": [\n    {\n      \"year\": 1983,\n      \"claim\": \"Establishing the molecular composition of Lp(a) was the first step: the question was what distinguishes Lp(a) from LDL, answered by showing it is apoB-100 disulfide-linked to a distinct high-molecular-weight glycoprotein.\",\n      \"evidence\": \"SDS-PAGE under reducing/non-reducing conditions with immunochemical and periodate-Schiff analysis\",\n      \"pmids\": [\"6219896\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not localize the disulfide bond or define the apo(a) sequence\", \"Site and timing of disulfide formation unaddressed\"]\n    },\n    {\n      \"year\": 1987,\n      \"claim\": \"Defined the genetic basis of plasma Lp(a) variation by showing apo(a) size heterogeneity is allelic at a single locus and inversely related to concentration, framing LPA as the primary determinant of Lp(a) levels.\",\n      \"evidence\": \"Reducing SDS-PAGE/immunoblotting, neuraminidase treatment, and family studies\",\n      \"pmids\": [\"2956279\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not establish the molecular mechanism linking isoform size to concentration\", \"Sialic acid excluded but other structural contributors not defined\"]\n    },\n    {\n      \"year\": 1981,\n      \"claim\": \"Tested whether Lp(a) uses the LDL receptor pathway and found it does not, opening the question of an alternative catabolic route.\",\n      \"evidence\": \"125I-ligand binding/degradation in normal, FH-heterozygous, and LDL-receptor-negative fibroblasts\",\n      \"pmids\": [\"6277537\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not identify the actual uptake receptor\", \"Mechanism of Lp(a) inhibition of LDL degradation unresolved\"]\n    },\n    {\n      \"year\": 1993,\n      \"claim\": \"Probed hepatic handling of Lp(a) and showed it binds hepatoma cells with low-affinity non-saturable kinetics and may be cleared by LDL-dependent 'hitchhiking', refining the catabolic model.\",\n      \"evidence\": \"Radioligand binding/degradation in HepG2 and Hep3B cells with antibody inhibition\",\n      \"pmids\": [\"8318510\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"Molecular identity of the hepatic binding site not defined\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Connected apo(a) structural homology to function by demonstrating Lp(a) binds plasminogen receptor sites bearing C-terminal lysines, providing a mechanism for interference with fibrinolysis.\",\n      \"evidence\": \"Saturation binding of radiolabeled Lp(a) on U937 and endothelial cells with ganglioside/enolase/lysine-analog competition\",\n      \"pmids\": [\"7667829\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not quantify the functional impact on plasminogen activation in vivo\", \"Specific receptor proteins not all identified\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Identified the VLDL receptor as a genuine Lp(a) catabolic receptor, with apo(a) rather than apoB mediating binding, resolving the long-standing alternative-pathway question.\",\n      \"evidence\": \"Receptor-expressing vs deficient fibroblasts, antibody/RAP inhibition, VLDLR-deficient mouse clearance, lesion immunohistochemistry\",\n      \"pmids\": [\"9410893\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative in vivo contribution of VLDLR vs other routes unquantified\", \"Does not explain hepatic clearance of the core particle\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Proposed a two-step assembly model (noncovalent kringle-LDL interaction then disulfide stabilization) plus renal proteolytic processing, framing where and how Lp(a) is built and cleared.\",\n      \"evidence\": \"Biochemical analysis of assembly intermediates, urinary apo(a) fragment identification, kringle-variant binding studies\",\n      \"pmids\": [\"9520125\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Some steps inferred rather than directly demonstrated\", \"Identity of the renal protease not established\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Addressed how covalent assembly is catalyzed by identifying a secreted, cofactor-dependent hepatoma oxidase activity that accelerates disulfide bond formation, distinct from PDI.\",\n      \"evidence\": \"In vitro Lp(a) assembly assay with conditioned medium, heat/ultrafiltration/dialysis fractionation, ping-pong kinetic analysis\",\n      \"pmids\": [\"16893192\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular identity of the oxidase not established\", \"Single lab; cofactor not identified\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Localized the noncovalent assembly step inside hepatocytes and showed it governs coupled apo(a)/apoB secretion, integrating assembly with cellular trafficking and secretion control.\",\n      \"evidence\": \"Co-IP, co-IF, PLA, pulse-chase, APOB siRNA, PCSK9/lomitapide perturbation in hepatocellular carcinoma cells with LBS-mutant apo(a)\",\n      \"pmids\": [\"35045727\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not identify the extracellular oxidase coupling to covalent assembly\", \"Performed in a 17K isoform context\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Defined a genetic cause of Lp(a) deficiency: a kringle IV-8 splice-donor mutation yielding truncated apo(a) that cannot form the covalent complex and is degraded, directly linking assembly competence to plasma persistence.\",\n      \"evidence\": \"RT-PCR of apo(a) transcription, expression of spliced cDNA in HepG2, plasma apo(a) immunoprecipitation\",\n      \"pmids\": [\"10484779\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not establish disease/phenotypic consequences of deficiency\", \"Why free truncated apo(a) is rapidly cleared not fully resolved\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Demonstrated genetic epistasis between LDLR status and Lp(a) levels independent of apo(a) genotype, showing LDLR deficiency raises Lp(a) despite LDLR not being the catabolic receptor.\",\n      \"evidence\": \"Sib-pair IBD analysis at the apo(a) locus with LDLR genotyping across 367 family members\",\n      \"pmids\": [\"9781014\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism reconciling LDLR effect on levels with non-LDLR catabolism unresolved\", \"Single analysis\"]\n    },\n    {\n      \"year\": 1990,\n      \"claim\": \"Linked Lp(a) to matrix retention and foam cell formation by showing enhanced proteoglycan/GAG complex formation driving macrophage cholesteryl ester accumulation, partly attributable to apo(a).\",\n      \"evidence\": \"In vitro GAG/PG complex formation, macrophage incubation, cholesteryl ester measurement with apo(a)-depleted controls\",\n      \"pmids\": [\"2146124\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"Apo(a)-independent component of binding not fully explained\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Showed cooperative matrix accumulation: smooth muscle cell chondroitin sulfate proteoglycans bind Lp(a) and pre-bound Lp(a) enhances subsequent LDL retention, a mechanism for lesional lipoprotein deposition.\",\n      \"evidence\": \"Radioligand binding to SMC matrix, chondroitinase analysis, binding affinity measurements\",\n      \"pmids\": [\"10323765\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Non-ionic interaction partners not molecularly defined\", \"Single lab\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Identified an endothelial pro-adhesive function: Lp(a) induces VCAM-1/E-selectin via intracellular calcium, mediated by apo(a) and independent of known lipoprotein receptors.\",\n      \"evidence\": \"HCAEC culture, adhesion molecule measurement, BAPTA/AM chelation, recombinant apo(a) competition, multiple receptor-blocking controls\",\n      \"pmids\": [\"9837867\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"The receptor/sensor transducing the calcium signal not identified\", \"Single lab\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Defined the molecular basis of Lp(a) proinflammatory signaling, showing apo(a)-borne oxidized phospholipids drive IL-8 through CD36/TLR2–MAPK–NF-\\u03baB/AP-1, tying a structural cargo to a signaling output.\",\n      \"evidence\": \"siRNA receptor knockdown, MAPK inhibitors, IL-8 promoter luciferase mutants, enzymatic oxPL removal, LBS-mutant apo(a) in THP-1/U937\",\n      \"pmids\": [\"26474593\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo relevance of the macrophage pathway not established here\", \"Contribution relative to other oxPL carriers unquantified\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Revealed an effect on vascular smooth muscle signaling: Lp(a) selectively down-regulates glucocorticoid receptor expression, blunting the antiproliferative action of glucocorticoids.\",\n      \"evidence\": \"Nuclear GR radioligand binding, GR mRNA Northern blotting, proliferation assays across cell and lipoprotein types\",\n      \"pmids\": [\"7649076\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Receptor/signal mediating GR down-regulation not identified\", \"Single lab\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Characterized Lp(a)-associated PAF-acetylhydrolase, showing most activity resides on the lipid/apoB core rather than apo(a) and is sensitive to particle oxidation.\",\n      \"evidence\": \"Density-gradient ultracentrifugation, DTT cleavage, PAF-AH activity and Cu2+-oxidation kinetics\",\n      \"pmids\": [\"8831934\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Physiological consequence of isoform-dependent kinetics unresolved\", \"Single lab\"]\n    },\n    {\n      \"year\": 1991,\n      \"claim\": \"Explained the relative oxidation resistance of Lp(a) by attributing its extended lag phase to high sialic acid content, demonstrated by neuraminidase removal and NANA reconstitution.\",\n      \"evidence\": \"Paired Cu2+ lipid peroxidation of Lp(a) and LDL, neuraminidase treatment, NANA reconstitution, composition analysis\",\n      \"pmids\": [\"1825020\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"In vivo relevance of differential oxidation kinetics not addressed\", \"Single lab\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Linked oxidized Lp(a) to endothelial injury, showing oxLp(a) is more potent than oxLDL at inducing apoptosis via superoxide and high lysophosphatidylcholine content.\",\n      \"evidence\": \"DNA fragmentation, Annexin V, TUNEL, superoxide measurement, SOD/catalase and DDTC manipulation, lysoPC quantification in HUVECs and rabbit aorta\",\n      \"pmids\": [\"10201010\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Upstream receptor/uptake route for oxLp(a) not defined\", \"Single lab\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Extended oxLp(a) endothelial signaling to autophagy, mapping a ROS-dependent PARP-1–LKB1–AMPK–mTOR axis.\",\n      \"evidence\": \"Autophagy and ROS assays, pathway inhibitor and SOD studies, Western blotting in HUVECs\",\n      \"pmids\": [\"26407666\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single cell type and lab\", \"Functional outcome of autophagy for cell fate not resolved\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Showed Lp(a) is a negative acute-phase reactant, declining during inflammation through decreased production rather than enhanced catabolism, integrating Lp(a) regulation with systemic inflammatory state.\",\n      \"evidence\": \"Serial plasma measurements in sepsis/burns patients, apo(a) fragment and urinary apo(a) assays, LPS-challenge mouse clearance study\",\n      \"pmids\": [\"10764684\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Transcriptional/hepatic mechanism of decreased production not defined\", \"Single lab\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Implicated Lp(a) in calcific aortic valve disease via interaction with autotaxin promoting valve mineralization, extending Lp(a) pathobiology beyond atherothrombosis.\",\n      \"evidence\": \"Mechanistic claim summarized in a review citing original work\",\n      \"pmids\": [\"28816078\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Primary experimental detail not available in this entry\", \"Direct Lp(a)–autotaxin interaction not independently characterized in the timeline\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The molecular identity of the extracellular oxidase that catalyzes covalent Lp(a) assembly, and how it integrates with the intracellular noncovalent assembly step, remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Oxidase enzyme unidentified\", \"Cofactor required for assembly unknown\", \"Coupling between hepatocyte secretion and extracellular covalent assembly undefined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0008289\", \"supporting_discovery_ids\": [13, 14, 20]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [4, 12, 16]},\n      {\"term_id\": \"GO:0008092\", \"supporting_discovery_ids\": [10, 11]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005783\", \"supporting_discovery_ids\": [8]},\n      {\"term_id\": \"GO:0005794\", \"supporting_discovery_ids\": [8]},\n      {\"term_id\": \"GO:0005768\", \"supporting_discovery_ids\": [8]},\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [0, 1]},\n      {\"term_id\": \"GO:0031012\", \"supporting_discovery_ids\": [10, 11]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [3, 8, 21]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [12, 13, 18]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [13, 17]}\n    ],\n    \"complexes\": [\"Lp(a) particle (apo(a)/apoB-100)\"],\n    \"partners\": [\"APOB\", \"VLDLR\", \"LDLR\", \"CD36\", \"TLR2\", \"PLG\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}